Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population
|
|
- Ursula Warner
- 6 years ago
- Views:
Transcription
1 Available online at Annals of Clinical & Laboratory Science, vol 36, no. 2, Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population Jude M. Abadie and Daniel D. Bankson Department of Laboratory Medicine, University of Washington Medical School, and Pathology and Laboratory Medicine Service, Veterans Affairs Puget Sound Health Care System, Seattle, Washington Abstract. This study evaluated serum κ and l free light chain (FLC) concentrations in a Veterans Affairs (VA) population. We hypothesized that our older, mostly male, population should not differ in serum FLC ranges from levels previously established for younger male and female populations and that the assay would improve our screening protocol for plasma cell dyscrasias (PCD). Serum κ and l FLC were assayed in 312 consecutive serum samples collected during a 16-week period from veterans whose clinical presentation indicated a need for serum protein electrophoresis (SPEP) analysis. We reviewed our laboratory information system (LIS) files to evaluate the patients diagnoses and treatment status in conjunction with serum FLC levels. All assays and validation studies were conducted using an immunoturbidimetric method with a Roche/Hitachi 911 modular analytical system. The intra-assay variability (CV) was <5%, based on 13 replicate assays of 4 control samples and 1 blank sample. Of the 312 patients, the SPEP results were normal in 235 and abnormal in 77. Of the 235 patients with normal SPEP results, 37 had abnormal FLC values and 20 of these were diagnosed as PCD. Of the 77 patients with abnormal SPEP results, only 9 had diagnoses unrelated to PCD. Using the FLC assay in conjunction with retrospective reviews of medical records, we obtained an 86% detection rate of PCD. This detection rate increased to 100% when both SPEP and FLC results were considered. In conclusion, this study documents an important role for serum FLC assays in diagnosing and monitoring PCD in a VA population. Our results support previously established serum FLC reference ranges that were obtained in younger, male and female populations. Using the serum FLC results in conjunction with SPEP results improves the sensitivity and specificity for managing VA patients whose clinical presentation indicates the need to evaluate PCD. Keywords: light chains, monoclonal gammopathy, myeloma, electrophoresis, plasma cell dyscrasia Introduction Multiple myeloma, a malignant plasma cell dyscrasia (PCD) associated with bone marrow plasmacytosis, is characterized by abnormal monoclonal immunoglobulin production. The neoplastic products of malignant plasma cells cause pathologic processes that include bone pain/fractures, renal failure, anemia, infection, hyperviscosity, and hypercalcemia [1,2]. A serum or urine monoclonal Address correspondence to Jude Abadie M.D., Ph.D.,Veterans Affairs Puget Sound Health Care System, 1660 S. Columbian Way (S-113-Lab), Seattle, Washington 98108, USA; fax ; judeabadie@medscape.com. component identified by immunofixation is the most common characteristic feature of monoclonal gammopathies [3]. Serum or urine immunoglobulin light chains may be the only finding in approximately 20% of myeloma patients [4]. While 24-hr urine samples contain high concentrations of light chains, their traditional use in clinical chemistry is often cumbersome, inaccurate, and difficult to measure by electrophoresis. Furthermore, changes in urinary M protein have been shown to correlate strongly with changes of serum free light chain (FLC) concentrations [4]. Therefore, serum FLC measurements may be better indices of disease progression than tests for Bence-Jones protein in urine /06/ $ by the Association of Clinical Scientists, Inc.
2 158 Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 A new quantitative nephelometric assay for serum FLCs has been used in several clinical investigations of PCD. The assay detects circulating monomeric and dimeric κ and l FLCs. These light chains are free in that they are unbound to a heavy chain immunoglobulin. Serum levels of κ and l FLCs, in conjunction with the FLC κ/l ratio, have been used with a high degree of sensitivity and specificity to identify and monitor FLC disease. Additional clinical use of the FLC assay includes monitoring disease stage in systemic primary amyloidosis, nonsecretory multiple myeloma, light chain deposition disease, and light chain multiple myeloma [5]. In such diseases, the underlying PCD can be difficult to detect or quantify by serum protein electrophoresis [6]. While immunofixation is the current gold standard for detecting monoclonal FLCs, that assay is qualitative and has sensitivities that vary among laboratories. A sensitive and specific quantitative serum FLC assay may prove to be an important guide for monitoring and treating patients with light chain disease. The clinical strength of the serum FLC assay as a pre-neoplastic marker may lie in its ability to assess the risk of progression from monoclonal gammopathy of undetermined significance (MGUS) to clinical PCD. This rate of progression is about 1% per year [7]. Specifically, an abnormal κ/l ratio has been reported to be the major independent risk factor for disease progression from MGUS; patients with normal ratios have low risk and do not require long-term monitoring [8,9]. We evaluated the serum FLC assay in a population of mostly male Veterans Affairs (VA) patients and compared our findings to results from studies using slightly younger, mixed-sex populations. Most published studies include a population based on all-comers and therefore reflect a younger mean age group and contain more females than would be observed in a VA population. While PCD is generally classified as a disease of the elderly, serum FLC reference ranges that have been used clinically in many investigations were established in a population of 282 normal subjects (men and women) from 20 to 90 years old [10]. Although both κ and l FLC levels increase with age, the κ/l ratio remains constant as a function of age. Increases in the levels of both κ and l FLC with advancing age have been attributed to declining renal function, inasmuch as significant increases in cystatin C were observed in the same patients. Increased FLC levels are also seen in conjunction with the incidence of MGUS, which has been reported to be ~1% in the general population >50 years of age and 3% in those >70 years of age [11]. We conducted this study to assess the utility of a serum FLC assay in our population of veterans whose clinical presentation led to a serum protein electrophoresis (SPEP) analysis. We decided to use the established reference ranges for serum κ and l FLC levels, hypothesizing that our older male population should not differ from other populations with respect to disease monitoring and test utility. Additionally, we evaluated the serum FLC assay on a Roche Hitachi 911 analyzer, an instrument not previously used in published studies describing the clinical utility of this assay. Materials and Methods This study was conducted using patients sera obtained from the Seattle division of the Veterans Affairs Puget Sound Health Care System hospital. During a 16-week period from 1 October 2004 through 1 February 2005, 312 consecutive patient serum samples (304 males and 8 females), which were routinely being evaluated by SPEP, were stored at -20 C and later assayed to determine levels of κ and l FLC. A previous investigation reported no significant differences in levels of κ or l serum FLC content or κ/l ratio between fresh and frozen samples [12]. We queried our laboratory information system (LIS) for relevant medical record information that included SPEP results, sex, and age. If a patient had more than one SPEP during the collection time period, only the initial sample was used to represent the results presented in this study. We also used the LIS to determine patient diagnoses and treatment status. All procedures were conducted in accordance with the ethical standards established by the University of Washington Medical Center and the Seattle VA Hospital Institutional Review Board. At the Veterans Affairs Puget Sound Health Care System assays of serum total protein concentrations were performed on the Hitachi Modular P analyzer (Roche Diagnostics, Indianapolis, IN) using the biuret technique. The clinical laboratory cites a reference range of g/dl for serum total protein concentration. Serum protein electrophoresis was performed using agarose gels and acid blue stain on the REP 1 system (Helena Laboratories, Beaumont, TX). Densitometric scans of serum protein electrophoresis gels were evaluated by two observers. Reference values for serum protein electrophoresis were: albumin g/dl; alpha-1 globulin g/dl; alpha-2 globulin g/dl; beta
3 Serum free light chain concentrations in a population of veterans 159 Table 1: Intra-assay performance of the serum FLC assay using a Roche/Hitachi 911 modular analytical system, based on 13 sets of replicate analyses of control and blank samples. Control & Mean CV ±2 SD range Blank samples (mg/l) (%) (mg/l) 27.7 mg/l l mg/l l mg/l k mg/l k Blank l Blank k globulin g/dl; and gamma globulin g/dl. The presence of one or more distinct peaks not corresponding to the usual protein bands in the gamma or beta globulin regions indicated the possible presence of a monoclonal or polyclonal gammopathy. Samples containing monoclonal peaks were further evaluated by immunofixation (Sebia, Norcross, GA). Serum κ and l FLCs were measured by immunoturbidimetry on a Hitachi 911 modular analytical system (Roche Diagnostics, Indianapolis, IN) using the FREELITE human κ and l kits (The Binding Site, San Diego, CA). The assay involves two separate measurements that result in the quantification of κ and l FLCs. Serum κ/l ratios are also computed. Patients with ratios >1.65 or <0.26 are identified as producing clonal κ or l FLCs, respectively. The normal serum reference ranges are mg/l for κ and mg/l for l. None of the results from this study were used for patient care. The assays were conducted during a 3-week period after all of the samples had been collected and after the validation studies had been completed (Table 1). Group means were compared by the t-test. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated for results obtained by SPEP, the serum FLC assay, and the combination of both tests. Table 2. Incidences of true or false positive and true or false negative results of screening for plasma cell disorders, based on SPEP and FLC assays of 312 consecutive serum samples. SPEP assays FLC assays (n and %) (n and %) True positive 27 (9%) 33 (11%) True negative 220 (71%) 271 (87%) False negative 15 (5%) 4 (1%) 12 myeloma 2 myeloma on 1 Waldenstrom s treatment* 1 AL amyloidosis 2 myeloma 1 lymphoma False positive or MGUS 50 (16%) 4 (1%) Total 312 (100%) 312 (100%) * Because the half-life of FLC is shorter than that of IgG, FLC concentrations can become normal in advance of IgG concentrations during treatment. Therefore, these 2 values may not represent false negative results. Table 3. Sensitivity, specificity, and predictive values of SPEP and FLC assays, and of the combination of both assays, in screening 312 serum samples for plasma cell disorders. Parameter SPEP FLC SPEP alone alone + FLC Sensitivity 64% 88% 100% Specificity 81% 98% 99% Positive predictive value 35% 88% 89% Negative predictive value 94% 98% 100% Results Table 1 lists the mean values, CVs, and ±2 SD ranges for 4 different control samples and 1 blank sample, based on 13 sets of replicate assays. The 17.8 mg/l κ control gave the smallest CV at 2.39%, and the 54.0 mg/l λ control gave the highest CV at 4.90%. The blank sample, which contained albumin (7 g/dl), yielded concentrations of 1.98 mg/l for κ and 2.74 mg/l for l, with CVs <5.0% for each. Long-term inter-assay CVs did not differ from the intra-assay results (data not shown). Table 2 lists the SPEP and FLC results for the 312 consecutive serum samples. In comparison to SPEP, the FLC assay results demonstrate higher percentages of true positives and true negatives and lower percentages of false positives and false negatives. Table 3 lists the overall sensitivities, specificities, and predictive values for SPEP, serum FLC, and both tests combined. Of the 312 consecutive specimens analyzed by SPEP and subsequently assayed for serum FLC, 235 were classified as normal and 77 were classified as abnormal based on SPEP results. The ages (mean ± SD) for the normal group (67.5 ± 9.8 yr) were not significantly different from the abnormal group (66.5 ± 10.7 yr). Of the 235 patients with normal SPEP results, 198 (84.3%) had normal κ and l values and ratios in conjunction with unremarkable clinical history or disease state. These 198 samples are not identified in Fig. 1, but the values would fit within the indicated box. However, 37 (15.7%) of the 235 patients with normal SPEP results were found to have abnormal κ/l ratio, abnormal FLC levels, or both. These 37 data points are plotted in Fig. 1. The log concentrations of serum κ and l levels
4 160 Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 Fig. 1. Abnormal serum FLC results in patients with normal SPEP results (n =37). Symbols: open circles = myeloma with abnormal κ/l ratio; solid circles = myeloma with normal κ/l ratio; open squares = non-myeloma with abnormal κ/l ratio; solid squares = polyclonal FLC. Fig. 2: Abnormal FLC results among patients with abnormal SPEP results (n = 41). Symbols: see Fig. 1.
5 Serum free light chain concentrations in a population of veterans 161 (mg/l) are plotted on the x- and y-axes, respectively. The boxed area represents the normal reference ranges for κ and l. The parallel lines represent the range of normal κ/l ratios. Of the 37 individuals with normal SPEP results and an abnormal FLC result, 17 had an abnormal κ/l ratio. These comprised 15 with multiple myeloma, 1 with lymphoma, and 1 with bladder transitional cell carcinoma. Of the 20 patients with a normal κ/l ratio, 3 were previously treated for myeloma, and the remaining 17 had diagnoses that were unrelated to plasma cell disorders. Fig. 2 shows the κ and l FLC levels for a portion of the 77 patients with an abnormal SPEP result. Of these 77 patients, 20 had both an abnormal κ/l ratio and a FLC level that was outside the reference ranges for κ and/or l. Of these 20, 12 had a diagnosis of multiple myeloma, and 2 were diagnosed with marginal cell lymphoma. The remaining 6 patients included Waldenstrom s macroglobulinemia, leiomyosarcoma, PCD osteomyelitis, or an unspecified diagnosis. Fifteen of the 77 abnormal SPEP patients had a normal κ/l ratio with a FLC level that was outside the reference ranges for κ and/or l. These patients were diagnosed with renal insufficiency, chronic anemia, smoldering myeloma with comorbidities, light chain disease, relapsed myeloma, or smoldering myeloma. The solid circles in Fig. 2 represent 6 of those 15 patients as well as 4 of the remaining 42 patients with a myeloma diagnosis but an abnormal SPEP and a normal κ/l ratio with FLC values that were within the reference ranges for both κ and l. The solid squares in Fig. 2 represent 9 of the 15 patients with a normal κ/l ratio but a κ and/or l FLC value outside the reference range. These included 3 patients with renal insufficiency, 1 with chronic anemia, and 5 with unspecified diagnoses. Discussion These results demonstrate the utility of the serum FLC assay for diagnosing and monitoring PCDs in a population of US military veterans. Previous studies have shown the value of this assay for diagnosis of light chain myeloma [6], nonsecretory myeloma [13], and primary amyloidosis [12]. In the results presented here, the serum free light chain assay was also valuable for detection of intact immunoglobulin myeloma. The detection rate for the serum free light chain assay in this study was 86% (25 of 29 PCDs). This is consistent with the only other report of the use of the serum free light chain assay in a clinical setting [5], in which the overall detection rate was 80.5%. Differences between the patient populations may account for the small difference in detection rate between that observed in the present study and that previously reported. Whereas the current study included primarily patients with intact immunoglobulin myeloma, 40% of the patients in the study by Katzmann et al [5] had MGUS or nonsecretory myeloma. It has been reported that excess FLCs are detected in 93% of patients with intact immunoglobulin myeloma, while 82% of nonsecretory patients produce excess levels of FLCs [12]. Therefore, the higher detection rate for the serum FLC assay in this study may reflect a different proportion of intact immunoglobulin myeloma patients, and signals the value of the serum FLC assay for detection and diagnosis of intact immunoglobulin myeloma. In contrast to the detection rate for the serum FLC assay, the detection rate for SPEP was only 48% (14 of 29 cases ofpcd). However, if SPEP and the serum FLC assay were used together, the detection rate for PCD was 100% (33 of 33 cases), albeit with a higher false positive rate. Thus an abnormal SPEP was found in 77 patients, but only 18% of these had a plasma cell disorder. On the other hand, there were 4 false positives for the serum FLC assay in this study. The specificity of the serum FLC assay in this study (99%) was clearly higher than for SPEP (77%). This indicates that the κ/l ratio is a sensitive and specific marker for monoclonal gammopathy. As the κ/l ratio is a measure of plasma cell clonality, it should not be surprising that an abnormal κ/l ratio is specific for monoclonal gammopathies. Because a number of disorders and diseases can increase production of immunoglobulins, there was a significant number of false positive SPEP results. At the same time, there were also several false negative SPEP results. There were fewer false positive and false negative results using the serum FLC assay. Furthermore, combining the serum
6 162 Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 FLC assay with SPEP resulted in significantly improved sensitivity, specificity, positive predictive value, and negative predictive value. These results indicate an important role for the serum FLC assay in screening for monoclonal gammopathies. The results of this study support our hypothesis that the established reference ranges for serum κ and l FLC levels remain valid for an older male population such as that at a Veterans Affairs Medical Center. We noted that the κ/l ratio, as computed from results of the serum FLC assay, is a sensitive and specific marker for PCDs. Addition of the serum FLC assay to a screening protocol that uses SPEP improves the sensitivity and specificity of the protocol. This will likely result in improved management of patients whose clinical presentation is suspicious for PCD. Such improved management could result in longer life and more productive quality of life for patients with PCD. Acknowledgements The authors thank Mr. James Garbin for technical assistance with FLC assays and Ms. Nancy Audino for LIS support. We also thank The Binding Site, Inc., for providing the FLC reagents and guidance regarding the FLC assay. References 1. Hallek M, Bergsagel P, Andersen P. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91: Tricot G. New insights into the role of microenvironment in multiple myeloma. Lancet 2000;335: Kyle R. Multiple myeloma. Review of 869 cases. Mayo Clin Proc 1975;50: Abraham R, Clark R, Bryant S, Larson T, Kyle R, Katzmann J. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48: Katzmann J, Abraham R, Dispenzier A, Lust J, Kyle R. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51: Lachmann H, Gallimore R, Carr-Smith H, Bradwell A, Pepys M, Hawkins P. Outcomes in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122: Bradwell A: Serum Free Light Chain Analysis, 3rd Ed. The Binding Site Ltd.; Birmingham, UK, 2005, pp Rajukumar S, Kyle R, Therneau T, Clark R, Bradwell A, Melton L, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;127: Bakshi N, Guilbranson R, Garstka D, Bradwell A, Keren D. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis (CZE) in detecting subtle FLC M-proteins. Am J Clin Pathol 2005;124: Katzmann J, Clark R, Abraham R, Bryant S, Lymp J, Bradwell A, Kyle R. Serum and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48: Kyle R, Rajkumar S. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999;13: Drayson M, Tang L, Drew R, Mead G, Carr-Smith H, Bradwell A. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97: Bradwell A, Carr-Smith H, Mead G, Harvey T, Brayson M. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
More informationUrine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples
Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationDiagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationSerum Free Light Chain Assays
Freelite Serum Free Light Chain Assays An aid to the diagnosis of: Light Chain (Bence Jones) Multiple Myeloma (LCMM) Nonsecretory Multiple Myeloma (NSMM) AL amyloidosis Light Chain Deposition Disease (LCDD)
More informationMultiple myeloma (MM) & related disorders
Multiple myeloma (MM) & related disorders Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial
More informationDiagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
Hutchison et al. BMC Clinical Pathology 2012, 12:12 TECHNICAL ADVANCE Open Access Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationMeasuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
More informationSerum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
More informationPerformance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins
Immunopathology / SEBIA CAPILLARYS 2 PARAPROTEIN DETECTION Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Zhaohai Yang, MD, PhD, Keith Harrison, MD,
More informationAssessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios
Clinical Chemistry 55:9 1646 1655 (2009) Cancer Diagnostics Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios Arthur R. Bradwell, 1,2* Stephen J.
More informationSerum Free Light Chain Analysis
Serum Free Light Chain Analysis Rajeevan Selvaratnam, Jing Cao and Amy B. Karger Introduction In healthy individuals, plasma cells originating from the bone marrow produce immunoglobulin molecules composed
More informationLaboratories and the New IMWG Myeloma Guidelines
Laboratories and the New IMWG Myeloma Guidelines David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu Speaker Disclosure In
More informationPrevalence of Monoclonal Gammopathy of Undetermined Significance
The new england journal of medicine original article Prevalence of Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle, M.D., Terry M. Therneau, Ph.D., S. Vincent Rajkumar, M.D., Dirk R.
More informationSharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
Clinical Chemistry 56:1 16 20 (2010) Clinical Case Study Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Kazunori Murata, 1 Raynell J. Clark, 1 Karen S. Lockington,
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016
MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to
More informationAnalytically coherent
ZO M OCTOBER 2017 N 7 sebia FLC Free light chain testing coherent with electrophoretic methods Analytically coherent SPE: 3.1 g/l FLC Nephelometry: 32.2 g/l FLC ELISA: 3.1 g/l Principle The sebia FLC Kappa
More informationThis Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.
MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationAccuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry
160 Annals of Clinical & Laboratory Science, vol. 33, no. 2, 2003 Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry C. Howard Tseng, 1 Chin-Yung Chang, 2 Kevin S. Liu, 3 and
More informationHUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA. Product Data Sheet. Cat. No.: RD R. For Research Use Only
HUMAN IMMUNOGLOBULIN FREE LIGHT CHAINS κ AND λ ELISA Product Data Sheet Cat. No.: RD194088100R For Research Use Only Page 1 of 36 VERSION 98 110511 18 CONTENTS 1. INTENDED USE 3 2. STORAGE, EXPIRATION
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationClinico hematological profile of multiple myeloma in tertiary care Hospital, Pune
Original article Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Dr. Sagale MS, Dr. Dangmali DP, Dr. Rane SR, Dr. Kulkarni KK, Dr. Puranik SC Department of Pathology,
More informationSerum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio
Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh
More informationEvaluation of Sebia s Capillarys 2 flex-piercing system in. level monoclonal protein in serum and urine of patients
Peer reviewed ORIGINAL ARTICLE Evaluation of Sebia s Capillarys 2 flex-piercing system in comparison with Hydrasys gel system, in identifying low level monoclonal protein in serum and urine of patients
More informationPolyclonal versus monoclonal immunoglobulin-free light chains quantification
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(3) 327 336! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563214553808 acb.sagepub.com
More informationCASE REPORT AND REVIEW OF THE LITERATURE
Page 76 / SA ORTHOPAEDIC JOURNAL Summer 2009 C ASE R EPORT AND R EVIEW OF THE L ITERATURE Low-secretory multiple myeloma HF Visser MBChB(Pret) Senior Registrar, Department Orthopaedic Surgery, University
More informationUnderstanding MGUS and Smoldering Multiple Myeloma
Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE
More informationIntroduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein.
Clin Chem Lab Med 2015; aop Point Josie A.R. Evans*, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding Quantification of β-region IgA monoclonal proteins shouldwe include immunochemical
More informationSingle Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells
Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,
More informationJournal of Immunological Methods
Journal of Immunological Methods 391 (2013) 1 13 Contents lists available at SciVerse ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper Development
More informationThe Incidence and Significance of Pseudoparaproteins in a Community Hospital
Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 289 The Incidence and Significance of Pseudoparaproteins in a Community Hospital Stephen Lewis Strobel Department of Pathology, St. Vincent
More informationSerum protein electrophoresis and immunofixation by a semiautomated electrophoresis system
Clinical Chemistry 44:5 944 949 (1998) Enzymes and Protein Markers Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system Xavier Bossuyt, * Ann Bogaerts, Gilberte Schiettekatte,
More informationSerum protein electrophoresis: Italian survey 1986
Ann Clin Biochem 1989; 26: 249-253 Serum protein electrophoresis: Italian survey 1986 F AGUZZI, C PETRINI'" and C GASPARRO From the Laboratorio Analisi Ospedali di Broni e Stradel/a, Pavia, and " Laboratorio
More informationSignificance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation
Original Article Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Sara L. Hall, 1 Jill Tate, 2 Devinder Gill, 1,3 *Peter Mollee 1,3
More informationAnion Gap and Immunoglobulin Concentration
Anion Gap and Immunoglobulin Concentration ALBERT A. KESHGEGIAN, M.D., PH.D. Keshgegian, Albert A.: Anion gap and immunoglobulin concentration. Am J Clin Pathol 74: 22-26,190. The serum anion gap is often
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationDiagnosis and staging
Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationSerum free light chain and Hevylite analyses in the diagnosis, monitoring and prognosis of B cell disorders
Klin. Biochem. Metab., 18 (39), 2010, No. 2, p. 56 61. Serum free light chain and Hevylite analyses in the diagnosis, monitoring and prognosis of B cell disorders Legg A. 1, Harding S. 1, Hughes R. G.
More informationMyeloma Primary Care. Dr R Lovell Feb 2015
Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/1.7314/APJCP.16.17..26 Robust Reference Intervals for Serum K and l Free Light Chains in Hyderabad, India: Myeloma Diagnostic Implications RESEARCH ARTICLE Robust Reference Intervals
More informationA Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma
MULTIPLE THE IRAQI POSTGRADUATE MYELOMA MEDICAL JOURNAL A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma Hind Shakir Ahmed ABSTRACT: BACKGROUND: Multiple myeloma (MM) is caused
More informationMultiple myeloma and its precursor disease (MGUS)
Review of the Health Effects in Vietnam Veterans Exposed to Herbicides: 11 th Biennial Update Meeting Multiple myeloma and its precursor disease (MGUS) Ola Landgren, M.D., Ph.D. Chief of Myeloma Service,
More informationMultiple Myeloma Patient Handbook
Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:
More information+ Serum Protein Electrophoresis with Immunofixation
+ Serum Protein Electrophoresis with Immunofixation Dr.Ajay Phadke Centre Head SRL Diagnostics-Dr.Avinash Phadke s Lab + What is electrophoresis? Electrophoresis is a method of separating proteins based
More informationLYMPHOPROLIFERATIVE. ALL- Acute Lymphoblastic leukemia. Non Hodgkin Lymphomas. Hodgkin Lymphomas. CLL-Chronic Lymphocytic Leukemia
של בדיקת Free Light Chains מקומה באבחון ומעקב של מיאלומה נפוצה ד"ר תמר תדמור מכון המטולוגי, בני ציון הקבוצה הישראלית למיאלומה נפוצה LYMPHOPROLIFERATIVE DISEASES ALL- Acute Lymphoblastic leukemia Non Hodgkin
More informationFRACTIONATION OF BENCE-JONES PROTEIN BY STARCH GEL ELECTROPHORESIS
J. clin. Path. (1958), 11, 334. FRACTIONATION OF BENCE-JONES PROTEIN BY STARCH GEL ELECTROPHORESIS BY F. V. FLYNN AND ELIZABETH A. STOW Fromti tile Department of Clinical Pathology, University College
More informationRESEARCH ARTICLE. Abstract. Introduction
RESEARCH ARTICLE The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationYour Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationHuman Immunoglobulin Free Light Chains Kappa and Lambda ELISA Kit
Human Immunoglobulin Free Light Chains Kappa and Lambda ELISA Kit Cat. No.:DEIA4632 Pkg.Size:96 T Intended use The Human Immunoglobulin Free Light Chains Kappa and Lambda ELISA kit contains two sandwich
More informationSERUM PROTEIN ELECTROPHORESIS
SERUM PROTEIN ELECTROPHORESIS ABD-ALLA BSC - OMDURMAN AHLIA HIGH DOPLOMA DGREE - ELZAEM EL-AZHARY FORMER HEAD OF HEMATOLOGY & BLOOD BANK MINISTRY OF HEALTH LABORATORY ADMINISTRATION KHARTOUM STATE MARKETING
More informationMichael L. Astion, 3 Joseph Rank,1 Mark H. Wener, Paul Torvik, Joe B. Schneider,1 and Lawrence M. Kilhingsworth 2
CLIN. CHEM. 41/9, 1328-1332 (1995) #{149} Oak Ridge Conference Electrophoresis-Tutor: An Image-Based Personal Corn puter Program That Teaches Clinical Interpretation of Protein Electrophoresis Patterns
More information7/6/2017. Learning Objectives
Learning Objectives Monoclonal Antibody Therapeutics Potential Interferents on Protein Electrophoresis and Related Tests Maria Alice V. Willrich, Ph.D., DABCC At the end of the presentation, participants
More information2. Relay characteristics of proteins and protein electrophoresis / fractionation.
UNIT: Proteins 15prot_elec.wpd Task Electrophoresis Objectives Upon completion of this exercise, the student will be able to: 1. Review electrophoresis information as presented in class. 2. Relay characteristics
More informationH-ferritin (Human) ELISA Kit
H-ferritin (Human) ELISA Kit Catalog Number KA0211 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationCapillary Zone Electrophoresis in the Evaluation of Serum Protein Abnormalities
Capillary Zone Electrophoresis in the Evaluation of Serum Protein Abnormalities David F. Keren, MD Key Words: Capillary zone electrophoresis; M-protein; Serum protein electrophoresis; monoclonal gammopathy;
More informationHighly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine
Clinical Chemistry 47:4 673 680 (2001) Enzymes and Protein Markers Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine Arthur R. Bradwell, 1* Hugh D. Carr-Smith,
More informationNephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light.
1 Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light. Light scattering is the physical phenomenon resulting from the interaction of light
More informationPreview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018
Preview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018 This document is only a SHORT PREVIEW of the Medifocus Guidebook on Multiple Myeloma. It is intended primarily to give
More informationMonitoring Multiple Myeloma
Monitoring Multiple Myeloma Kyle A. Udd, BS, Tanya M. Spektor, PhD, and James R. Berenson, MD Mr Udd is a medical research data analyst at the Institute for Myeloma & Bone Cancer Research in West Hollywood,
More informationKeywords: exercise; free light chains; immunoglobulins; renal function. Introduction
Clin Chem Lab Med 2015; aop John P. Campbell a, *, Thijs M.H. Eijsvogels a, Yanyun Wang, Maria T.E. Hopman and Joannes F.M. Jacobs Assessment of serum free light chain levels in healthy adults immediately
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Craig Emmitt Cole, MD University of Michigan Comprehensive Cancer Center What are Blood Cancers, What IS Multiple Myeloma?
More informationConvenient and Effective Method for Removing Fibrinogen from Serum Specimens before Protein Electrophoresis
Clinical Chemistry 49:6 868 872 (2003) Proteomics and Protein Markers Convenient and Effective Method for Removing Fibrinogen from Serum Specimens before Protein Electrophoresis Ling L. Qiu, 1 Stanley
More informationTransient Paraproteinemia: An Intriguing Immunological Anomaly
Annals of Clinical & Laboratory Science, vol. 33, no. 3, 2003 265 Transient Paraproteinemia: An Intriguing Immunological Anomaly Stephen L. Strobel Department of Pathology, St. Vincent Mercy Medical Center,
More informationApplication Note for Gentian Cystatin C Immunoassay on. ABX Pentra 400 1, Horiba Medical 1 v03en-june 2011
Page 1 of 5 Application Note for Gentian Cystatin C Immunoassay on For in vitro diagnostic use only ABX Pentra 400 1, Horiba Medical 1 v03en-june 2011 Intended Use The Gentian Cystatin C Immunoassay is
More informationSerum Protein Electrophoresis
Serum Protein Electrophoresis A Comparison of the Use of Thin-layer Agarose Gel and Cellulose Acetate Louis ROSENFELD, PH.D. Department of Pathology, Clinical Chemistry Laboratory, New York University
More informationAAG PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
IMMAGE Immunochemistry Systems Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Alpha 1 -Acid Glycoprotein REF 447780 (150 tests) For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by:
More informationMultiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective
Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective *Rahman MM, 1 Aziz MA, 2 Islam MM, 3 Zaman AM, 4 Afrose S, 5 Khan MA 6 Treatment of multiple myeloma, a plasma
More informationFlow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle
Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell
More informationIgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup
IgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup High Throughput Methods to Maximize the Use of the PA 800 Plus system Jose-Luis Gallegos-Perez
More informationCytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels
Published Ahead of Print on February 1, 2018, as doi:10.3324/haematol.2017.184226. Copyright 2018 Ferrata Storti Foundation. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum
More informationPoor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma
ARTICULO ORIGINAL Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma Gabriela Zamora-Ortiz,*, ** Sara Velázquez-Sánchez-de-Cima,*,
More informationMeasurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John
Measurement of free light chains with assays based on monoclonal antibodies Te Velthuis, Henk; Drayson, Mark; Campbell, John DOI:.55/cclm-25-963 License: None: All rights reserved Document Version Peer
More informationDiagnosis of Multiple Myeloma from a Blood Sample Failed To Be Centrifuged: A Case Report
Diagnosis of Multiple Myeloma from a Blood Sample Failed To Be Centrifuged: A Case Report Limin Zhang 1, Hong Lv 1, Kelin Chen 1, Fang Fang 2, Ruimin Ma 1, Guanghui Zheng 1, Jingzheng Liu 1, Chunqing Shao
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationWhat does it mean for general practice?
The New Zealand Laboratory Schedule and Test Guidelines: What does it mean for general practice? 2 November 2013 best tests A new schedule for laboratory testing in New Zealand In October, 2013, a new
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationCyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100
Product information Information about other products is available at: www.demeditec.com Userś Manual Cyfra 21-1 IRMA The CYFRA 21.1 IRMA system provides a direct in vitro quantitative determination of
More informationTHE IMPORTANCE OF FREE LIGHT CHAINS OF IMMUNOGLOBULINS DETERMINATION IN SERUM
JMB 2007; 26 (4) DOI: 10.2478/v10011-007-0032-6 UDK 577.1 : 61 ISSN 1452-8258 JMB 26: 269 273, 2007 Original paper Originalni nau~ni rad THE IMPORTANCE OF FREE LIGHT CHAINS OF IMMUNOGLOBULINS DETERMINATION
More informationBCH 462. Single Radial Immunodiffusion and Immuno-electrophoresis
BCH 462 Single Radial Immunodiffusion and Immuno-electrophoresis Immunoassays tests include: 1. Precipitation. 2. Agglutination. 3. Immunofluorescence. 4. Radioimmunoassay (RIA). 5. Enzyme-Linked Immuno
More informationElectro refers to electron flow or current. Thus Electrophoresis is movement under electric current.
ELECTROPHORESIS Electrophoresis Electro refers to electron flow or current. Phoresis refers to movement. Thus Electrophoresis is movement under electric current. This technique therefore can separate molecules
More informationSerum Protein Electrophoretic Pattern as a Differential Diagnostic Tool
Serum Protein Electrophoretic Pattern as a Differential Diagnostic Tool Dr. George Gborienemi Simeon (Corresponding Author) Department of Medical Laboratory, Niger Delta University, Bayelsa State, Nigeria.
More informationClinical Chemistry Approach to Evaluation of Commutability
Clinical Chemistry Approach to Evaluation of Commutability Hubert W. Vesper, Ph.D. Director, Clinical Standardization Programs Division of Laboratory Sciences Centers for Disease Control and Prevention,
More informationMultiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
Heaney et al. BMC Nephrology (2017) 18:247 DOI 10.1186/s12882-017-0661-z RESEARCH ARTICLE Open Access Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free
More informationAugust 2017 Changes. Flow Cytometry Checklist. CAP Accreditation Program
August 2017 Changes Flow Cytometry Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.21.2017 Disclaimer and Copyright Notice
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationUnderstanding Your Blood and Blood Tests
Myeloma Canada InfoGuide Series Understanding Your Blood and Blood Tests www.myeloma.ca Introduction This InfoGuide is for people living with myeloma, their families and their caregivers. It will help
More informationImmunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016
Immunological Techniques in Research and Clinical Medicine Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016 Antibodies Remarkable Tools for Research and Diagnosis You can make an antibody
More informationIGRAs for Serial Testing of Healthcare Workers
IGRAs for Serial Testing of Healthcare Workers Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding
More informationCHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) THYROID STIMULATING HORMONE (FERRITIN) Ferritin
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland hills CA 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationStep-by-Step Description of ELISA
Step-by-Step Description of ELISA The protocols in this kit rely on indirect antibody capture ELISA. The steps in this assay are: Step 1: Antigen is added to the wells of the microplate strip and incubated
More informationCLEARLLAB LS LYMPHOID SCREEN REAGENT
CLEARLLAB LS LYMPHOID SCREEN REAGENT CE MARKED ANTIBODY COMBINATION FOR LEUKEMIA / LYMPHOMA ANALYSIS Because Your Patient is Her Everything BECAUSE YOUR PATIENT IS HER EVERYTHING ClearLLab LS Lymphoid
More informationLeukemia (2013) 27, & 2013 Macmillan Publishers Limited All rights reserved /13
Leukemia (2013) 27, 213 219 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu ORIGINAL ARTICLE Immunoglobulin heavy/light chain ratios improve paraprotein detection
More informationBrian GM Durie. Black Swan Research Initiative (BSRI) Purpose
Black Swan Research Initiative Brian GM Durie Saturday August 22, 2015 1 Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which
More information